In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

The two highest-ranking leaders within the FDA’s Office of Prescription Drug Promotion (OPDP) have stepped down, according to ...

When Phathom Pharmaceuticals launched its first direct-to-consumer ads for Voquezn | In a commercial debuting Monday, Kenan ...

The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...

For a second time in less than a month, a new CDMO has uncloaked.  | For a second time in less than a month, a new CDMO has ...

Particulate contamination has sparked the recalls of numerous injectable drugs over the years, with Amneal’s hospital med ...

Pharma brands spend billions annually trying to engage healthcare providers (HCPs), yet much of this outreach has a limited ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

As tariff threats and FDA staff cuts thrust the biopharma world into uncharted waters, President Donald Trump is offering the ...